IQVIA and Kexing Biopharm Strengthen AI-Powered Global Clinical Development and Regulatory Strategy for Biosimilars
IQVIA is expanding its strategic collaboration with Kexing Biopharm in a move designed to accelerate the global development and commercialization of biosimilar medicines through AI-enabled clinical research capabilities, advanced analytics, and integrated regulatory support. The collaboration reflects the growing convergence of artificial intelligence, data-driven clinical operations, and global biopharmaceutical expansion strategies as healthcare companies seek faster and more efficient pathways for bringing biosimilars to international markets.
The agreement strengthens the relationship between the two companies as Kexing Biopharm advances its broader internationalization strategy. Kexing, listed on the Shanghai Stock Exchange under stock code 688136.SH, focuses primarily on the research, production, and commercialization of recombinant protein therapies and microecological pharmaceutical products. Through the expanded collaboration, the company aims to accelerate development timelines, improve regulatory efficiency, and expand the global reach of its biosimilar portfolio.
Biosimilars are biologic medicines designed to closely replicate already approved reference biologics whose patents have expired. These therapies play an increasingly important role in global healthcare systems because they can improve patient access to critical biologic treatments while helping reduce healthcare costs. However, biosimilar development remains highly complex, involving demanding regulatory requirements, sophisticated manufacturing standards, extensive clinical evaluation, and large-scale international trial coordination.
As competition intensifies in the biosimilars market, pharmaceutical companies are increasingly turning to AI-powered clinical research and advanced data infrastructure to optimize development programs and reduce operational inefficiencies. The collaboration between IQVIA and Kexing Biopharm highlights how artificial intelligence is becoming deeply embedded across the pharmaceutical development lifecycle, particularly within clinical trial operations and regulatory planning.
Under the expanded partnership, IQVIA will provide end-to-end support across multiple stages of biosimilar development and commercialization. This includes clinical development services, regulatory strategy guidance, advanced data analytics, global trial execution, patient insights, and commercialization planning. The companies are working under a coordinated global operating framework intended to streamline international biosimilar expansion while maintaining high standards of scientific rigor and product quality.
A central component of the collaboration involves the integration of IQVIA’s AI-enabled clinical trial technologies. These capabilities are designed to improve the speed, efficiency, and quality of clinical research processes while enabling faster and more informed decision-making throughout development programs.
Artificial intelligence will be utilized across several key operational areas, including clinical protocol design, trial site selection, patient recruitment optimization, study execution, and operational monitoring. By applying AI-driven analytics and predictive modeling to these workflows, the companies aim to reduce development delays, improve trial efficiency, and enhance overall study performance.
Protocol design is one of the areas where AI can provide significant value. Designing effective clinical trial protocols traditionally requires balancing scientific objectives, regulatory expectations, patient recruitment feasibility, operational logistics, and statistical validity. AI systems can analyze historical trial data, patient populations, and regulatory precedents to help optimize trial structures and reduce the likelihood of costly amendments or delays later in the process.
Similarly, AI-assisted site identification may improve the speed and effectiveness of global clinical trial deployment. Selecting appropriate research sites is critical for successful biosimilar development because patient enrollment rates, data quality, compliance standards, and operational execution can vary significantly across regions and institutions. AI-powered systems can help identify high-performing trial locations based on historical performance data, patient availability, and operational metrics.
The collaboration also reflects broader industry efforts to modernize clinical research through automation and advanced analytics. Traditional clinical development processes often involve significant operational complexity, lengthy timelines, fragmented data systems, and high costs. Pharmaceutical companies are increasingly investing in digital transformation initiatives that use AI, cloud infrastructure, real-world data, and predictive analytics to streamline research workflows and improve development productivity.
For biosimilar developers specifically, operational efficiency is particularly important because the market is highly competitive and cost-sensitive. Unlike novel biologic drugs, biosimilars are often developed within narrower pricing and profitability frameworks. Companies therefore face strong pressure to optimize clinical timelines and reduce unnecessary development costs while still satisfying stringent regulatory requirements.
IQVIA’s role in the collaboration extends beyond operational execution. The company is also contributing strategic guidance around international regulatory navigation and market expansion. Biosimilar approvals require compliance with diverse regulatory frameworks across different regions, including the United States, Europe, Asia-Pacific markets, and emerging economies.
Managing these regulatory pathways can be especially challenging for companies pursuing simultaneous multi-market commercialization strategies. Regulatory agencies may require varying levels of clinical evidence, analytical comparability data, manufacturing documentation, and post-market monitoring commitments.
By integrating regulatory strategy with clinical operations and analytics, IQVIA aims to help Kexing Biopharm reduce risk while improving efficiency in overseas registration processes. This coordinated approach could prove valuable as Kexing attempts to expand its biosimilar portfolio beyond domestic markets and establish a stronger international commercial presence.
Brian Mi, President of Asia Pacific at IQVIA, said the collaboration demonstrates the company’s ability to combine biosimilar expertise, AI-powered technologies, and global operational infrastructure to support Kexing’s international growth strategy.
According to Mi, the partnership brings together IQVIA’s scientific capabilities, global execution network, and advanced analytics platform to accelerate biosimilar development while navigating the complexities of international healthcare markets.
The collaboration also reflects the increasing globalization of the biosimilars sector itself. Historically, many biosimilar markets developed regionally, with companies focusing primarily on domestic or select international territories. However, growing global demand for affordable biologic therapies is encouraging companies to pursue broader multinational development and commercialization strategies.
This trend is especially visible among Chinese biopharmaceutical companies, many of which are increasingly expanding beyond local markets into North America, Europe, Latin America, and other international regions. Partnerships with global clinical research and healthcare intelligence firms such as IQVIA can provide critical infrastructure and expertise necessary to support these international ambitions.
Yanqing Zhao, General Manager of Kexing Biopharm, stated that the strategic collaboration is expected to accelerate the company’s internationalization efforts and improve its ability to execute global biosimilar programs efficiently.
Zhao highlighted several key areas where IQVIA’s capabilities are expected to support Kexing’s development strategy, including access to global healthcare data resources, AI-enabled clinical optimization, patient insights, regulatory expertise, and overseas market registration support.
The use of AI within the partnership also reflects broader changes occurring across the life sciences industry. Artificial intelligence is increasingly being applied not only to drug discovery, but also to operational aspects of pharmaceutical development, including clinical trial management, patient engagement, pharmacovigilance, supply chain forecasting, and regulatory compliance.
In clinical development specifically, AI has the potential to significantly reduce some of the inefficiencies that have historically contributed to high research costs and lengthy timelines. Delays in patient recruitment, protocol amendments, site underperformance, and operational bottlenecks are among the most common causes of extended development schedules.
AI systems can help identify patterns and risks earlier in the process, enabling proactive adjustments that improve trial execution and reduce costly disruptions. Machine learning models may also support adaptive trial management by continuously analyzing operational data throughout the study lifecycle.
The collaboration between IQVIA and Kexing Biopharm illustrates how these technologies are moving from experimental pilot projects into large-scale operational deployment within real-world pharmaceutical programs.
At the same time, the partnership underscores the growing importance of integrated service models in global drug development. Rather than treating clinical research, regulatory affairs, analytics, and commercialization as separate operational silos, companies are increasingly adopting unified development frameworks that coordinate these functions under a centralized strategic approach.
This integration can improve visibility across programs, reduce duplication of effort, accelerate decision-making, and strengthen alignment between development objectives and commercial outcomes.
IQVIA’s broader business model is built around this integrated approach. The company combines clinical research services, healthcare analytics, commercial consulting, real-world evidence capabilities, and AI-driven operational technologies to support pharmaceutical and biotechnology clients across the full product lifecycle.
For Kexing Biopharm, the collaboration represents an opportunity to leverage global infrastructure and expertise while scaling its own biosimilar development operations internationally.
The global biosimilars market itself is expected to continue growing rapidly over the coming decade as patents for major biologic therapies expire and healthcare systems seek more cost-effective treatment alternatives. Demand is particularly strong in oncology, immunology, endocrinology, and autoimmune disease categories where biologic therapies often carry extremely high treatment costs.
As the market expands, companies capable of accelerating development timelines while maintaining regulatory and scientific quality standards may gain important competitive advantages.
The partnership between IQVIA and Kexing Biopharm demonstrates how AI, advanced analytics, and globally coordinated clinical infrastructure are becoming increasingly central to achieving those objectives. By combining biosimilar expertise with AI-enabled clinical operations and international regulatory support, the two companies are positioning themselves to compete more aggressively in the evolving global biologics market.
The collaboration also highlights a larger transformation occurring across healthcare and life sciences, where artificial intelligence is steadily becoming embedded within the core operational frameworks of pharmaceutical development rather than functioning solely as a supplemental technology layer.
As global pharmaceutical companies continue seeking faster, more efficient, and more scalable development strategies, partnerships built around integrated AI-powered research ecosystems are likely to become an increasingly important part of the future biosimilars landscape.
Source link: https://www.businesswire.com
